Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM21 CAR-T Cells in Elderly R/R Multiple Myeloma
NCT04537442Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IM21 in multiple myeloma (MM), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of adverse events at 1 month. Status: unknown.
02
Drugs
IM21
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04537442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537442.